Literature DB >> 7620015

The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group.

I W Fong1, E Toma.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is usually a fatal neurological disease. The natural history of PML in patients with human immunodeficiency virus infection was analyzed. The correlations between CD4+ lymphocyte count, previous diagnosis of AIDS, treatment with cytarabine, and survival time are reported for 28 individuals for whom the diagnosis of PML was confirmed by histopathologic examination. For 16 patients (57%), PML was the AIDS-defining illness. For these 16 patients, the mean (+/- SD) survival time after presentation was 7.5 +/- 7.6 months (range, 1-31 months), whereas that for the 12 patients (43%) for whom AIDS was previously diagnosed was 3.2 +/- 2.8 months (range, 1-11 months) (P = .01). The overall mean (+/- SD) CD4+ cell count was 85 +/- 82/mm3 (range, 12-349/mm3). The mean (+/- SD) survival time for patients with CD4+ cell counts of > or = 90/mm3 at the time of presentation was 9.4 +/- 8.7 months, while that for patients with CD4+ cell counts of < 90/mm3 at the time of presentation was 3.6 +/- 1.8 months (P = .03). The nine patients did not benefit from treatment with cytarabine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620015     DOI: 10.1093/clinids/20.5.1305

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

Review 1.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

2.  Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team.

Authors:  M J Post; C Yiannoutsos; D Simpson; J Booss; D B Clifford; B Cohen; J C McArthur; C D Hall
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

3.  Activities of various compounds against murine and primate polyomaviruses.

Authors:  G Andrei; R Snoeck; M Vandeputte; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era.

Authors:  A Antinori; A Ammassari; M L Giancola; A Cingolani; S Grisetti; R Murri; L Alba; B Ciancio; F Soldani; D Larussa; G Ippolito; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 5.  HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment.

Authors:  Lauren N Bowen; Bryan Smith; Daniel Reich; Martha Quezado; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2016-10-27       Impact factor: 42.937

Review 6.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.

Authors:  Hiroki Yokoyama; Takashi Watanabe; Dai Maruyama; Sung-Won Kim; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-10-15       Impact factor: 2.490

7.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

Authors:  W Royal; B Dupont; D McGuire; L Chang; K Goodkin; T Ernst; M J Post; D Fish; G Pailloux; H Poncelet; M Concha; L Apuzzo; E Singer
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 8.  Opportunistic infections of the CNS in patients with AIDS: diagnosis and management.

Authors:  Julio Collazos
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Central nervous system infections in individuals with HIV-1 infection.

Authors:  Arunima Mamidi; Joseph A DeSimone; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

Review 10.  JC virus: an oncogenic virus in animals and humans?

Authors:  Melissa S Maginnis; Walter J Atwood
Journal:  Semin Cancer Biol       Date:  2009-02-24       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.